Raymond James Financial Services Advisors
CRBU icon

Raymond James Financial Services Advisors’s Caribou Biosciences CRBU Stock Holding History

Raymond James Financial Services Advisors’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-26,252
Closed -$150K – 3402
2023
Q4 		$150K Buy
+26,252
New +$130K ﹤0.01% 3063

Other funds holding CRBU

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $416M AUM 11.87% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Raymond James Financial Services Advisors's CRBU Position: Q1 2024 in Review

Raymond James Financial Services Advisors sold out of Caribou Biosciences (CRBU) in Q1 2024, closing a stake of 26,252 shares — an estimated $150K sold.

Raymond James Financial Services Advisors first reported a position in CRBU in Q4 2023 and held it in 1 quarter. The position peaked at $150K in Q4 2023. 151 funds tracked by Wall St. Rank hold CRBU as of Q1 2024.

  • Raymond James Financial Services Advisors reported no remaining Caribou Biosciences position as of Q1 2024 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 26,252 Caribou Biosciences shares in Q1 2024, an estimated $150K.
  • Raymond James Financial Services Advisors first reported a position in Caribou Biosciences in Q4 2023 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Caribou Biosciences position peaked at $150K in Q4 2023.
  • 151 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2024, filed 22 Apr 2024.